Search Results - N. A. Avxentyev

  • Showing 1 - 15 results of 15
Refine Results
  1. 1
    Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation

    Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation by N. A. Avxentyev, Yu. V. Makarova

    Published 2022-10-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable <i>BRAF</i> V600-mutated metastatic melanoma in Russia

    Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable <i>BRAF</i> V600-mutated metastatic melanoma in Russia by N. A. Avxentyev, Yu. V. Makarova

    Published 2023-11-01
    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA

    PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA by N. A. Avxentyev, M. Yu. Frolov

    Published 2016-09-01
    Get full text
    Article

    Save to List
    Saved in:
  4. 4
    Modeling the impact of using trastuzumab deruxtecan in patients with breast cancer on reducing cancer mortality in Russia

    Modeling the impact of using trastuzumab deruxtecan in patients with breast cancer on reducing cancer mortality in Russia by N. A. Avxentyev, Yu. V. Makarova, A. S. Makarov

    Published 2024-07-01
    Get full text
    Article

    Save to List
    Saved in:
  5. 5
    Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer

    Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer by N. A. Avxentyev, A. S. Makarov, M. Yu. Frolov

    Published 2019-01-01
    Get full text
    Article

    Save to List
    Saved in:
  6. 6
    Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia

    Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia by N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov

    Published 2018-08-01
    Get full text
    Article

    Save to List
    Saved in:
  7. 7
    Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer

    Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer by N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov

    Published 2020-02-01
    Get full text
    Article

    Save to List
    Saved in:
  8. 8
    Pharmacoeconomic analysis of everolimus immunosuppressive therapy for <i>de novo</i> kidney transplant recipients in Russia

    Pharmacoeconomic analysis of everolimus immunosuppressive therapy for <i>de novo</i> kidney transplant recipients in Russia by N. A. Avxentyev, E. V. Derkach, E. I. Prokopenko

    Published 2019-05-01
    Get full text
    Article

    Save to List
    Saved in:
  9. 9
    Estimating long-term overall survival with olaparib as maintenance therapy in patients with newly diagnosed advanced ovarian cancer with BRCA mutations

    Estimating long-term overall survival with olaparib as maintenance therapy in patients with newly diagnosed advanced ovarian cancer with BRCA mutations by N. A. Avxentyev, S. V. Khokhlova, M. Yu. Frolov, A. S. Makarov

    Published 2021-10-01
    Get full text
    Article

    Save to List
    Saved in:
  10. 10
    Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma

    Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma by N. A. Avxentyev, E. M. Pazuhina, G. S. Tumyan, P. A. Zeynalova

    Published 2020-12-01
    Get full text
    Article

    Save to List
    Saved in:
  11. 11
    PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION

    PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION by M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach

    Published 2015-06-01
    Get full text
    Article

    Save to List
    Saved in:
  12. 12
    METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY

    METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY by N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov

    Published 2016-09-01
    Get full text
    Article

    Save to List
    Saved in:
  13. 13
    HEALTHCARE SPENDING EFFICIENCY IN RUSSIAN REGIONS

    HEALTHCARE SPENDING EFFICIENCY IN RUSSIAN REGIONS by N. A. Avxentyev, V. M. Baydin, O. A. Zarubina, N. N. Sisigina, S. A. Kulkova

    Published 2016-02-01
    Get full text
    Article

    Save to List
    Saved in:
  14. 14
    Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review

    Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literat... by N. A. Avxentyev, I. I. Andreyashkina, E. V. Artamonova, L. V. Bolotina, E. I. Kovalenko, N. N. Sisigina

    Published 2024-05-01
    Get full text
    Article

    Save to List
    Saved in:
  15. 15
    Modeling the impact of CDK4 / 6 inhibitors on reducing cancer mortality

    Modeling the impact of CDK4 / 6 inhibitors on reducing cancer mortality by N. A. Avxentyev, E. V. Bilan, A. Yu. Goryainova, Yu. V. Makarova, R. A. Murashko, A. V. Sobolev, S. V. Sharov, D. Yu. Yukalchuk

    Published 2025-05-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: